L-Serine ( DrugBank: Serine, L-Serine )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 2 |
2. 筋萎縮性側索硬化症
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03580616 (ClinicalTrials.gov) | October 24, 2018 | 26/6/2018 | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study | Amyotrophic Lateral Sclerosis (ALS) | Drug: L-Serine | Elijah W. Stommel | Brain Chemistry Labs, Institute for Ethnomedicine | Recruiting | 18 Years | N/A | All | 50 | Phase 2 | United States |
2 | NCT01835782 (ClinicalTrials.gov) | January 2013 | 27/3/2013 | Determining the Safety of L-serine in ALS | Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses. | Amyotrophic Lateral Sclerosis (ALS) | Drug: L-Serine | Phoenix Neurological Associates, LTD | Institute for Ethnomedicine | Active, not recruiting | 18 Years | 85 Years | Both | 20 | Phase 1/Phase 2 | United States |